Prostate cancer glycan markers and autoantibody signatures

US7981625B2 · kind B2 · utility

Assignee

• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Denong Wang · Menlo Park, US
• Leonore A. Herzenberg · Stanford, US
• Donna M. Peehl · Mountain View, US
• Leonard A. Herzenberg · Stanford, US

Key dates

• Filing date: Apr 10, 2009
• Grant date: Jul 19, 2011
• Expiry date: Jun 22, 2029

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2400/10
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Disclosed are methods for probing the immunogenic sugar moieties of prostate cancer cells. The methods detect a number of glyco-epitopes that are highly and differentially expressed among prostate cancers of various Gleason grades. The glyco-epitopes exist on the surfaces of prostate cells. The methods also comprise the detection of autoantibodies in prostate cancer subjects. The antibodies bound to a glyco-motif of N-glycans that is normally “cryptic.” This target is highly expressed in prostate cancers. Lectins and antibodies that detect these glyco-epitopes that expressed in prostate cancer tissues include Euonymus europaeus lectin (EEL); Psophocarpus Tetragonolobus Lectin-I (PTL-I); Griffonia Simplicifolia Lectin-I-A4 (GSL-I-A4); Griffonia Simplicifolia Lectin-I-B4 (GSL-I-B4); Sambucus nigra I agglutinin (SNA-I; Phaseolus vulgaris-L (PHA-L; Galanthus nivalis agglutinin (GNA); Narcissus pseudonarcissus agglutinin (NPA); Artocarpus integrifolia agglutinin (Jacalin); and mAb TM10 (IgM).